Detailed Information
Cited 3 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Primary results of ALESIA: Phase III, randomised open-label study of alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naive ALK plus advanced non-small-cell lung cancer (NSCLC)
- Authors
- Zhou, C[Zhou, C.]; Lu, Y[Lu, Y.]; Kim, SW[Kim, S-W.]; Reungwetwattana, T[Reungwetwattana, T.]; Zhou, J[Zhou, J.]; Zhang, Y[Zhang, Y.]; He, J[He, J.]; Yang, JJ[Yang, J-J.]; Cheng, Y[Cheng, Y.]; Lee, SH[Lee, S. H.]; Bu, L[Bu, L.]; Xu, T[Xu, T.]; Yang, L[Yang, L.]; Wang, C[Wang, C.]; Morcos, PN[Morcos, P. N.]; Mitry, E[Mitry, E.]; Li, Z[Li, Z.]
- Issue Date
- Nov-2018
- Publisher
- OXFORD UNIV PRESS
- Citation
- ANNALS OF ONCOLOGY, v.29, pp.174 - 174
- Indexed
- SCIE
SCOPUS
- Journal Title
- ANNALS OF ONCOLOGY
- Volume
- 29
- Start Page
- 174
- End Page
- 174
- ISSN
- 0923-7534
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.